Published in Blood Weekly, August 7th, 2003
Scientists in Austria described the case of a 35-year-old female AML patient "who underwent allogeneic stem cell transplantation (SCT) in second complete remission (CR)".
This patient received "reduced-intensity conditioning with fludarabine and 2 Gy of total body irradiation," noted E. Prinz and coauthors at University Hospital Vienna. "For graft-versus-host disease (GVHD) prophylaxis, cyclosporin A (CsA) and mycophenolate mofetil (MMF) were given."
"On day 27 after SCT complete hematological remission and donor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.